Home LiteratureArticle Details
PMID: 12941910 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.

Journal of virology ·Vol. 77 ·No. 18 ·2003-09-00 ·Pages 9993-10003

Johnson WE, Sanford H, Schwall L, Burton DR, Parren PW, Robinson JE, Desrosiers RC

Abstract

Simian immunodeficiency virus (SIV) of macaques isolate SIVmac239 is highly resistant to neutralization by polyclonal antisera or monoclonal antibodies, a property that it shares with most primary isolates of human immunodeficiency virus type 1 (HIV-1). This resistance is important for the ability of the virus to persist at high levels in vivo. To explore the physical features of the viral envelope complex that contribute to the neutralization-resistant phenotype, we examined a panel of SIVmac239 derivatives for sensitivity to neutralization by a large collection of monoclonal antibodies (MAbs). These MAbs recognize both linear and conformational epitopes throughout the viral envelope proteins. The variant viruses included three derivatives of SIVmac239 with substitutions in specific N-linked glycosylation sites of gp120 and a fourth variant that lacked the 100 amino acids that encompass the V1 and V2 loops. Also included in this study was SIVmac316, a variant of SIVmac239 with distributed mutations in env that confer significantly increased replicative capacity in tissue macrophages. These viruses were chosen to represent a broad range of neutralization sensitivities based on susceptibility to pooled, SIV-positive plasma. All three of these very different kinds of mutations (amino acid substitutions, elimination of N-glycan attachment sites, and a 100-amino-acid deletion spanning variable loops V1 and V2) dramatically increased sensitivity to neutralization by MAbs from multiple competition groups. Thus, the mutations did not simply expose localized epitopes but rather conferred global increases in neutralization sensitivity. The removal of specific N-glycan attachment sites from V1 and V2 led to increased sensitivity to neutralization by antibodies recognizing epitopes from both within and outside of the V1-V2 sequence. Surprisingly, while most of the mutations that gave rise to increased sensitivity were located in the N-terminal half of gp120 (surface subunit [SU]), the greatest increases in sensitivity were to MAbs recognizing the C-terminal half of gp120 or the ectodomain of gp41 (transmembrane subunit [TM]). This reagent set and information should now be useful for defining the physical, structural, thermodynamic, and kinetic factors that influence relative sensitivity to antibody-mediated neutralization.

MeSH Terms
Animals Antibodies, Monoclonal/immunology Antibodies, Viral/immunology Antibody Specificity HIV Envelope Protein gp120/chemistry,immunology HIV Envelope Protein gp41/immunology Immunoglobulin Fab Fragments/immunology Macaca mulatta Mice Mutation Neutralization Tests Simian Immunodeficiency Virus/immunology Viral Envelope Proteins/chemistry,immunology
Chemicals
Antibodies, Monoclonal Antibodies, Viral HIV Envelope Protein gp120 HIV Envelope Protein gp41 Immunoglobulin Fab Fragments Viral Envelope Proteins
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Johnson Welkin E
New England Regional Primate Research Center, Department of Microbiology and Molecular Genetics, Harvard Medical School, One Pine Hill Drive, Box 9102, Southborough, MA 01772-9102, USA.
Sanford Hannah
Schwall Linda
Burton Dennis R
Parren Paul W H I
Robinson James E
Desrosiers Ronald C
References (69)
69 references, click to expand
  1. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.
    Science. 1984 May 4;224(4648):500-3 PMID: 6200936
  2. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques.
    Science. 1985 Jun 7;228(4704):1201-4 PMID: 3159089
  3. Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III.
    Science. 1985 Oct 4;230(4721):71-3 PMID: 2412295
  4. Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus.
    J Gen Virol. 1987 Dec;68 ( Pt 12):3183-9 PMID: 2826656
  5. Use of infectious molecular clones of simian immunodeficiency virus for pathogenesis studies.
    J Med Primatol. 1989;18(3-4):305-9 PMID: 2760916
  6. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes.
    Nature. 1999 Feb 4;397(6718):436-41 PMID: 9989410
  7. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.
    Annu Rev Immunol. 1999;17:657-700 PMID: 10358771
  8. Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells.
    J Virol. 1999 Jul;73(7):5373-80 PMID: 10364284
  9. HIV's evasion of the cellular immune response.
    Immunol Rev. 1999 Apr;168:65-74 PMID: 10399065
  10. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells.
    Immunity. 1999 Jun;10(6):661-71 PMID: 10403641
  11. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    J Virol. 1995 Sep;69(9):5723-33 PMID: 7543586
  12. Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.
    J Virol. 1996 Jun;70(6):3668-77 PMID: 8648701
  13. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.
    J Virol. 1996 Jun;70(6):3724-33 PMID: 8648707
  14. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.
    AIDS. 1995;9 Suppl A:S117-36 PMID: 8819579
  15. HIV-1 antibody--debris or virion?
    Nat Med. 1997 Apr;3(4):366-7 PMID: 9095159
  16. Core structure of gp41 from the HIV envelope glycoprotein.
    Cell. 1997 Apr 18;89(2):263-73 PMID: 9108481
  17. Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries.
    J Mol Biol. 1997 Apr 4;267(3):684-95 PMID: 9126846
  18. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor.
    J Virol. 1997 Sep;71(9):6296-304 PMID: 9261346
  19. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.
    J Virol. 1997 Oct;71(10):7719-27 PMID: 9311856
  20. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.
    J Virol. 1997 Oct;71(10):7895-902 PMID: 9311879
  21. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein.
    J Virol. 1997 Dec;71(12):9808-12 PMID: 9371651
  22. Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque.
    J Virol. 1998 Jan;72(1):585-92 PMID: 9420262
  23. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.
    Nature. 1998 Jan 22;391(6665):397-401 PMID: 9450757
  24. A role for carbohydrates in immune evasion in AIDS.
    Nat Med. 1998 Jun;4(6):679-84 PMID: 9623976
  25. Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein.
    J Virol. 1998 Jul;72(7):5399-407 PMID: 9620994
  26. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.
    J Virol. 2000 Feb;74(4):1961-72 PMID: 10644369
  27. Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.
    J Virol. 2000 Sep;74(17):7922-35 PMID: 10933700
  28. HIV-1 membrane fusion: targets of opportunity.
    J Cell Biol. 2000 Oct 16;151(2):F9-14 PMID: 11038194
  29. Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection.
    Virology. 2000 Oct 25;276(2):229-37 PMID: 11040114
  30. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants.
    J Virol. 2001 Mar;75(5):2041-50 PMID: 11160708
  31. gp120: Biologic aspects of structural features.
    Annu Rev Immunol. 2001;19:253-74 PMID: 11244037
  32. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.
    J Virol. 2001 Apr;75(8):3903-15 PMID: 11264379
  33. The antiviral activity of antibodies in vitro and in vivo.
    Adv Immunol. 2001;77:195-262 PMID: 11293117
  34. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
    J Virol. 2001 Nov;75(22):10892-905 PMID: 11602729
  35. Viral persistence: HIV's strategies of immune system evasion.
    Annu Rev Med. 2002;53:499-518 PMID: 11818487
  36. The challenge of viral reservoirs in HIV-1 infection.
    Annu Rev Med. 2002;53:557-93 PMID: 11818490
  37. A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope.
    J Virol. 2002 Mar;76(5):2075-86 PMID: 11836385
  38. The simian immunodeficiency viruses.
    Annu Rev Immunol. 1990;8:557-78 PMID: 2188674
  39. Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys.
    J Virol. 1991 Apr;65(4):1843-54 PMID: 2002545
  40. The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus.
    AIDS Res Hum Retroviruses. 1990 Nov;6(11):1221-31 PMID: 2078405
  41. Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins.
    AIDS. 1991 Jul;5(7):829-36 PMID: 1716442
  42. Complex determinants of macrophage tropism in env of simian immunodeficiency virus.
    J Virol. 1992 Apr;66(4):2067-75 PMID: 1548752
  43. Human infection by genetically diverse SIVSM-related HIV-2 in west Africa.
    Nature. 1992 Aug 6;358(6386):495-9 PMID: 1641038
  44. Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies.
    AIDS Res Hum Retroviruses. 1992 Jun;8(6):1147-51 PMID: 1380261
  45. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.
    Nature. 1993 Mar 25;362(6418):355-8 PMID: 8455722
  46. Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys.
    J Virol. 1993 Jul;67(7):4104-13 PMID: 8510218
  47. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
    J Virol. 1993 Nov;67(11):6642-7 PMID: 7692082
  48. Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.
    J Virol. 1994 Apr;68(4):2624-31 PMID: 7511176
  49. Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence.
    Curr Top Microbiol Immunol. 1994;188:185-219 PMID: 7523031
  50. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.
    J Virol. 1995 Jan;69(1):101-9 PMID: 7527081
  51. Viral dynamics in human immunodeficiency virus type 1 infection.
    Nature. 1995 Jan 12;373(6510):117-22 PMID: 7529365
  52. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.
    Nature. 1995 Jan 12;373(6510):123-6 PMID: 7816094
  53. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules.
    Virology. 1995 Jan 10;206(1):713-7 PMID: 7530400
  54. HIV entry and its inhibition.
    Cell. 1998 May 29;93(5):681-4 PMID: 9630213
  55. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.
    Science. 1998 Jun 19;280(5371):1884-8 PMID: 9632381
  56. Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides.
    Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9134-9 PMID: 9689046
  57. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.
    J Virol. 1998 Oct;72(10):7840-5 PMID: 9733820
  58. Production and characterization of SIV envelope-specific rhesus monoclonal antibodies from a macaque asymptomatically infected with a live SIV vaccine.
    AIDS Res Hum Retroviruses. 1998 Sep 20;14(14):1253-62 PMID: 9764909
  59. Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins.
    Virology. 1998 Sep 30;249(2):367-78 PMID: 9791028
  60. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.
    J Virol. 1998 Dec;72(12):10270-4 PMID: 9811774
  61. CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity.
    J Virol. 2002 Mar;76(6):2595-605 PMID: 11861825
  62. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.
    Virology. 2001 Nov 10;290(1):59-73 PMID: 11883006
  63. Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies.
    J Biol Chem. 2002 Mar 29;277(13):11456-64 PMID: 11805109
  64. Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus.
    J Virol. 2003 Jan;77(1):375-81 PMID: 12477842
  65. Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120.
    J Virol. 2003 Jan;77(1):560-70 PMID: 12477860
  66. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.
    Nature. 2002 Dec 12;420(6916):678-82 PMID: 12478295
  67. Antibody neutralization and escape by HIV-1.
    Nature. 2003 Mar 20;422(6929):307-12 PMID: 12646921
  68. Rapid evolution of the neutralizing antibody response to HIV type 1 infection.
    Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9 PMID: 12644702
  69. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).
    Science. 1983 May 20;220(4599):868-71 PMID: 6189183
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2003-09-00
Pages
9993-10003
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC224602
Subset
IM
Grants
NIAID NIH HHS · AI 33292 · United States
NCRR NIH HHS · RR 00168 · United States
NCRR NIH HHS · P51 RR000168 · United States
NCRR NIH HHS · K26 RR000168 · United States
NIAID NIH HHS · R01 AI050421 · United States
NIAID NIH HHS · R37 AI033292 · United States
NIAID NIH HHS · R01 AI033292 · United States
NIAID NIH HHS · AI 28243 · United States
NIAID NIH HHS · AI 44293 · United States
NIAID NIH HHS · AI 35365 · United States
NIAID NIH HHS · P01 AI035365 · United States
NIAID NIH HHS · AI 50421 · United States
NIAID NIH HHS · U01 AI035365 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com